PMID- 21046136
OWN - NLM
STAT- MEDLINE
DCOM- 20120119
LR  - 20141120
IS  - 1432-0711 (Electronic)
IS  - 0932-0067 (Linking)
VI  - 284
IP  - 3
DP  - 2011 Sep
TI  - The HER2 gene copies per tumor cell either before or after correction for 
      chromosome-17 correlated significantly with HER2 IHC results in epithelial 
      ovarian cancer in a tissue microarray study.
PG  - 721-9
LID - 10.1007/s00404-010-1708-6 [doi]
AB  - BACKGROUND: HER2 gene amplification and HER2 protein overexpression are important 
      factors in predicting clinical sensitivity to anti-HER2 monoclonal antibody 
      therapy in breast cancer patients. The purpose of this study is to evaluate the 
      correlation between HER2 protein expressions and the HER2 gene copies per tumor 
      cell either before or after chromosome-17 correction in epithelial ovarian cancer 
      (EOC). METHODS: Adopting 2007 ASCO/CAP guideline recommendations for HER2 
      testing, 27 tissue microarray (TMA) samples from EOC patients were analyzed by 
      immunohistochemistry (IHC) using Dako, c-erb-B2 antibody and subsequently 
      examined by fluorescence in situ hybridization (FISH) using Abbott/Vysis, 
      PathVysion HER2 DNA Probe Kit. RESULTS: The overall concordance revealed 81.5% 
      between HER2 IHC and HER2 FISH results. Additionally, HER2 gene copies prior to 
      chromosome-17 correction increased significantly in a stepwise order through the 
      negative, equivocal, and positive IHC result categories (P = 0.026), as did the 
      HER2 gene copies after chromosome-17 correction (P = 0.028). On the other hand, 
      HER2 IHC results correlated significantly with both chromosome-17 uncorrected 
      HER2 gene copy numbers (rho = 0.430, P = 0.025) and chromosome-17 corrected HER2 
      gene copy numbers (rho = 0.524, P = 0.027). CONCLUSION: We demonstrated that both 
      chromosome-17 corrected and uncorrected HER2 gene copies correlated significantly 
      with HER2 IHC result categories; and tests for the HER2 gene copies per tumor 
      cell either before or after correction for chromosome-17 can be applied as a 
      potentially valuable tool in analyzing the HER2 status in EOC.
FAU - Tsai, Wen-Chih
AU  - Tsai WC
AD  - Department of Obstetrics and Gynecology, Po-Jen General Hospital, Taipei, Taiwan.
FAU - Lee, Ming-Yung
AU  - Lee MY
FAU - Chen, Fong-Lin
AU  - Chen FL
FAU - Wang, Po-Hui
AU  - Wang PH
FAU - Lin, Wea-Lung
AU  - Lin WL
FAU - Ruan, Alexandra
AU  - Ruan A
FAU - Li, Yi-Ju
AU  - Li YJ
FAU - Wang, Shao-Chuan
AU  - Wang SC
FAU - Chiang, Hung
AU  - Chiang H
FAU - Han, Chih-Ping
AU  - Han CP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101103
PL  - Germany
TA  - Arch Gynecol Obstet
JT  - Archives of gynecology and obstetrics
JID - 8710213
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Chromosomes, Human, Pair 17/*genetics
MH  - Female
MH  - Gene Amplification
MH  - *Gene Dosage
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Microarray Analysis
MH  - Ovarian Neoplasms/*genetics/metabolism
MH  - Receptor, ErbB-2/*genetics/metabolism
MH  - Statistics, Nonparametric
EDAT- 2010/11/04 06:00
MHDA- 2012/01/20 06:00
CRDT- 2010/11/04 06:00
PHST- 2010/05/06 00:00 [received]
PHST- 2010/08/24 00:00 [accepted]
PHST- 2010/11/04 06:00 [entrez]
PHST- 2010/11/04 06:00 [pubmed]
PHST- 2012/01/20 06:00 [medline]
AID - 10.1007/s00404-010-1708-6 [doi]
PST - ppublish
SO  - Arch Gynecol Obstet. 2011 Sep;284(3):721-9. doi: 10.1007/s00404-010-1708-6. Epub 
      2010 Nov 3.